Transforming growth factor-beta expression in human testicular neoplasms. 1998

M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
Department of Experimental Medicine and Pathology, La Sapienza University, Rome, Italy. 2494@mclink.it

OBJECTIVE To investigate the localization of transforming growth factors (TGF-beta 1, -beta 2 and -beta 3) and their receptors (TGF-beta RI and RII). METHODS The study included 26 paraffin-embedded tissues from human testicular neoplasms: 15 seminomas, 2 embryonal carcinomas, 1 immature teratoma, 4 immature teratomas with embryonal carcinoma, 1 immature teratoma with seminoma, 1 seminoma with embryonal carcinoma and 2 gonadal stromal tumors (Leydig cell tumors). RESULTS TGF-beta 1 immunoreactivity was cytoplasmic and was expressed in 22 (84.6%), TGF-beta 2 in 20 (77%), TGF-beta 3 in 11 (42.3%), TGF-beta-RI in 21 (80.8%) and TGF-beta-RII in 18 (69.2%) of the 26 neoplasms. The percentage of positive immunostained cells and the intensity of staining were significantly higher in tumor than in peritumor nonneoplastic testis. In the peritumor nonneoplastic testis, Leydig, Sertoli and germ cells coexpressed both the three TGF-beta isoforms and TGF-beta-RI and RII. The myoepithelial cells of the seminiferous tubules showed immunoreactivity for TGF-beta RI and RII but not for TGF-beta s. In tumor testis areas the pattern of TGF-beta and TGF-beta receptor expression and distribution varied according to the histologic type of testicular tumor. Seminomas showed a diffuse pattern of TGF-beta immunoreactivity, whereas immature teratomas had focal and patchy distribution. In teratomas, differentiated structures contained more TGF-beta s than undifferentiated structures.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007984 Leydig Cell Tumor Gonadal interstitial or stromal cell neoplasm composed of only LEYDIG CELLS. These tumors may produce one or more of the steroid hormones such as ANDROGENS; ESTROGENS; and CORTICOSTEROIDS. Clinical symptoms include testicular swelling, GYNECOMASTIA, sexual precocity in children, or virilization (VIRILISM) in females. Interstitial Cell Tumor,Interstitial Cell Tumors,Tumor, Interstitial Cell,Tumor, Leydig Cell,Tumors, Interstitial Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077293 Receptor, Transforming Growth Factor-beta Type I A transmembrane serine-threonine kinase that forms a heteromeric complex with TYPE II TGF-BETA RECEPTORS to bind TGF-BETA and regulate a variety of physiological and pathological processes including CELL CYCLE ARREST; CELL PROLIFERATION; CELL DIFFERENTIATION; WOUND HEALING; EXTRACELLULAR MATRIX production, immunosuppression and ONCOGENESIS. Activin Receptor-like Kinase 5,Receptor, TGF-beta Type I,Serine-Threonine-Protein Kinase Receptor R4,TGF-beta RPK,TGF-beta Receptor Protein Kinase,TGF-beta Type I Receptor,TGF-beta Type I Receptors,TGFBR1,TbetaR-I Kinase,Transforming Growth Factor beta Receptor I,Transforming Growth Factor, beta Receptor 1,Type I TGF-beta Receptor,Type I TGF-beta Receptors,Activin Receptor like Kinase 5,Kinase, TbetaR-I,Serine Threonine Protein Kinase Receptor R4,TGF beta Receptor Protein Kinase,TGF beta Type I Receptor,TGF beta Type I Receptors,TbetaR I Kinase,Type I TGF beta Receptor,Type I TGF beta Receptors
D000077294 Receptor, Transforming Growth Factor-beta Type II A transmembrane serine-threonine kinase that forms a heteromeric complex with TYPE I TGF-BETA RECEPTORS when bound to TGF-BETA. This receptor complex regulates a variety of physiological and pathological processes including CELL CYCLE ARREST; CELL PROLIFERATION; CELL DIFFERENTIATION; WOUND HEALING; EXTRACELLULAR MATRIX production, immunosuppression and ONCOGENESIS. TGF-beta Type II Receptor,TGF-beta Type II Receptors,TGFBR2,TbetaR-II Kinase,Transforming Growth Factor-beta Type II Receptor,Transforming Growth Factor-beta Type II Receptors,Type II TGF-beta Receptor,Type II TGF-beta Receptors,Kinase, TbetaR-II,Receptor, Transforming Growth Factor beta Type II,TGF beta Type II Receptor,TGF beta Type II Receptors,TbetaR II Kinase,Transforming Growth Factor beta Type II Receptor,Transforming Growth Factor beta Type II Receptors,Type II TGF beta Receptor,Type II TGF beta Receptors
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
September 1992, The American journal of pathology,
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
September 1997, Investigative ophthalmology & visual science,
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
July 1993, Journal of reproductive immunology,
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
August 1997, The American journal of pathology,
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
December 1997, European journal of cancer (Oxford, England : 1990),
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
March 1994, Thorax,
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
March 1991, European journal of haematology,
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
September 1992, Laboratory investigation; a journal of technical methods and pathology,
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
February 2002, Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University,
M R Cardillo, and E Petrangeli, and L Ravenna, and L Salvatori, and F Di Silverio
March 1999, Biochimica et biophysica acta,
Copied contents to your clipboard!